<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04027816</url>
  </required_header>
  <id_info>
    <org_study_id>RT001-009</org_study_id>
    <nct_id>NCT04027816</nct_id>
  </id_info>
  <brief_title>A Natural History Study of Infantile Neuroaxonal Dystrophy</brief_title>
  <official_title>Protocol RT001-009: A Natural History Study of Infantile Neuroaxonal Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Retrotope, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Retrotope, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a longitudinal and prospective study of the natural history of infantile&#xD;
      neuroaxonal dystrophy (INAD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After obtaining informed consent, the study participants' relevant medical records will be&#xD;
      collected and reviewed for this study. Next, a clinic visit will be scheduled with the&#xD;
      patient's family and an observing MD/DO/MBBS from a sponsor site to confirm and clarify&#xD;
      information in the medical records.&#xD;
&#xD;
      A baseline evaluation of clinical status will also be performed during this visit to serve as&#xD;
      visit one in this longitudinal, prospective natural history study. Subsequent visits will&#xD;
      take place every 6 months, for up to 24 months. Key components of this prospective study at&#xD;
      each visit include a neurodevelopment exam tailored for INAD, application of the CHOP-INTEND&#xD;
      neurodevelopment scale, the Hammersmith infant neurological examination and the modified&#xD;
      Ashworth spasticity scale as well as collection of monthly parental severity scoring and&#xD;
      monthly home videos of activities of daily living (ADLs).&#xD;
&#xD;
      Data from this study will be pooled and presented in aggregate, without identification of&#xD;
      individual subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 17, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>INAD Mortality</measure>
    <time_frame>1-2 years of follow-up is planned</time_frame>
    <description>Overall analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>INAD Morbidity</measure>
    <time_frame>1-2 years of follow-up is planned</time_frame>
    <description>Videotaped, structured neurological assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INAD Morbidity</measure>
    <time_frame>1-2 years of follow-up is planned</time_frame>
    <description>CHOP-INTEND Neuro-development Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INAD Morbidity</measure>
    <time_frame>1-2 years of follow-up is planned</time_frame>
    <description>Hammersmith infant neurological examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INAD morbidity</measure>
    <time_frame>1-2 years of follow-up is planned</time_frame>
    <description>Modified Ashworth spasticity scale</description>
  </secondary_outcome>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Neuroaxonal Dystrophy, Infantile</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Living males or females with a diagnosis of classic INAD between 18 months to 10 years of&#xD;
        age.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female 18 months to 10 years of age&#xD;
&#xD;
          -  Medical history consistent with the symptoms of classic INAD (onset of symptoms&#xD;
             between the ages of 6 months and 3 years)&#xD;
&#xD;
          -  Homozygous or compound heterozygous PLA2G6 variants&#xD;
&#xD;
          -  Signed informed consent form (ICF) prior to entry into the registry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of atypical NAD (ANAD)&#xD;
&#xD;
          -  Additional underlying diagnosis with features that overlap with INAD&#xD;
&#xD;
          -  Unwilling or unable to allow medical record review&#xD;
&#xD;
          -  Unwilling or unable to participate in serial assessments every 6 months (including&#xD;
             deceased patients)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Milner, MD</last_name>
    <role>Study Director</role>
    <affiliation>Retrotope, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Centre</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EN1 Neuro Services Pvt. Ltd</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Faisal Specialist Hospital and Research Center</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Neurology of Tunis</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Egypt</country>
    <country>India</country>
    <country>Saudi Arabia</country>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 16, 2019</study_first_submitted>
  <study_first_submitted_qc>July 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2019</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PLA2G6-related NBIA</keyword>
  <keyword>INAD</keyword>
  <keyword>PLA2G6</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroaxonal Dystrophies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

